Flexion Therapeutics (NASDAQ:FLXN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

Several other research analysts also recently commented on the company. Janney Montgomery Scott boosted their target price on Flexion Therapeutics to $570.00 and gave the stock a “fair value” rating in a research note on Tuesday, October 10th. Wells Fargo & Co set a $39.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a report on Friday, October 6th. Needham & Company LLC restated a “buy” rating and set a $36.00 price target on shares of Flexion Therapeutics in a report on Sunday, September 17th. Royal Bank of Canada set a $44.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, Northland Securities restated a “buy” rating and set a $40.00 price target on shares of Flexion Therapeutics in a report on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Flexion Therapeutics has an average rating of “Buy” and an average target price of $106.25.

Shares of Flexion Therapeutics (NASDAQ FLXN) traded up $0.21 during midday trading on Tuesday, reaching $25.79. The company’s stock had a trading volume of 593,700 shares, compared to its average volume of 626,843. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. The firm has a market capitalization of $971.56, a P/E ratio of -7.33 and a beta of 1.14. Flexion Therapeutics has a 12-month low of $16.51 and a 12-month high of $32.25.

In related news, insider Michael D. Clayman bought 5,000 shares of Flexion Therapeutics stock in a transaction that occurred on Wednesday, November 8th. The shares were acquired at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the acquisition, the insider now directly owns 35,395 shares of the company’s stock, valued at approximately $835,322. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Neil Bodick bought 2,700 shares of Flexion Therapeutics stock in a transaction that occurred on Tuesday, November 21st. The stock was bought at an average price of $24.49 per share, for a total transaction of $66,123.00. Following the completion of the acquisition, the insider now directly owns 64,605 shares of the company’s stock, valued at $1,582,176.45. The disclosure for this purchase can be found here. Insiders own 15.98% of the company’s stock.

A number of hedge funds have recently made changes to their positions in FLXN. Fiduciary Trust Co. bought a new stake in Flexion Therapeutics in the second quarter valued at approximately $101,000. Advisor Group Inc. boosted its holdings in Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 3,500 shares during the last quarter. SG Americas Securities LLC bought a new stake in Flexion Therapeutics in the third quarter valued at approximately $135,000. IFP Advisors Inc boosted its holdings in Flexion Therapeutics by 58.1% in the third quarter. IFP Advisors Inc now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $194,000 after acquiring an additional 2,950 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new stake in Flexion Therapeutics in the third quarter valued at approximately $235,000. Institutional investors and hedge funds own 72.78% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/flexion-therapeutics-flxn-raised-to-hold-at-zacks-investment-research/1803004.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.